{"id":"NCT01270464","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma","officialTitle":"A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2011-01-05","resultsPosted":"2016-06-06","lastUpdate":"2016-06-06"},"enrollment":315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Asthma"],"interventions":[{"type":"DRUG","name":"Reslizumab","otherNames":["Cinquil","humanized monoclonal antibody","CEP-38072"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Reslizumab - 0.3 mg/kg","type":"EXPERIMENTAL"},{"label":"Reslizumab - 3.0 mg/kg","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1).","primaryOutcome":{"measure":"Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures","timeFrame":"Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16","effectByArm":[{"arm":"Placebo","deltaMin":0.126,"sd":0.0549},{"arm":"Reslizumab - 0.3 mg/kg","deltaMin":0.242,"sd":0.0556},{"arm":"Reslizumab - 3.0 mg/kg","deltaMin":0.286,"sd":0.0548}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0018"},{"comp":"OG000 vs OG001","p":"0.0237"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":89,"countries":["United States","Argentina","Belgium","Brazil","Canada","Colombia","France","Hungary","Israel","Mexico","Netherlands","Poland","Sweden"]},"refs":{"pmids":["27056586"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":105},"commonTop":["Asthma","Headache","Nasopharyngitis"]}}